| 摘要: |
| 目的 探讨鼠神经生长因子联合蕲蛇酶注射液治疗急性脑梗死的临床疗效。方法 急性脑梗死136例患者按入院时间随机分为治疗组(n=68)和对照组(n=68)，2组均采用常规治疗，包括口服阿司匹林，合理控制血压、血糖，调脂，降低颅压及其合并症和有关并发症的处理；对照组采用血栓通600 mg及蕲蛇酶注射液0.75 U分别加入0.9%氯化钠注射液250 mL中静脉滴注，每日1次，连用14 d；治疗组在对照组基础上应用鼠神经生长因子18 μg，肌肉注射，每日1次，连用14 d；比较2组患者住院期间美国国立卫生研究院卒中量表(national institutes of health stroke scale，NIHSS)评分和牛津残障评分(Oxford disability score，OHS)的变化、治疗显效率及总有效率，观察2组患者不良反应的发生情况。结果 治疗组疗效明显优于对照组(P<0.05)，治疗前治疗组和对照组NIHSS评分及OHS评分比较，差异均无统计学意义；疗程第21天，治疗组NIHSS评分及OHS评分均显著优于对照组(P<0.05)，治疗组显效率和总有效率(72.1%和94.1%)显著高于对照组(58.8%和86.8%)(P<0.05)。结论 鼠神经生长因子联合蕲蛇酶注射液可有效改善急性脑梗死患者的神经功能，且效果优于单用蕲蛇酶注射液。 |
| 关键词: 鼠神经生长因子 蕲蛇酶注射液 脑梗死 疗效 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Clinical Observation of Mouse Nerve Growth Factor Combined With Acutobin Injection on Acute Cerebral Infarction |
|
PEI Zhengbin
|
|
Chongqing Jiulongpo District Hospital of Chinese Medicine, Chongqing 400080, China
|
| Abstract: |
| OBJECTIVE To investigate the clinical efficacy of acute cerebral infarction treated by nerve growth factor combined with acutobin injection. METHODS One hundred and sixty-eight patients with acute cerebral infarction were randomly divided into treatment group(n=68) and control group(n=68) according to admission time. Two groups were treated with conventional therapy including oral aspirin, the reasonable control of blood pressure, blood glucose, lipid, and reducing the intracranial pressure and complications and related complications treatment. The control group adopted intravenous injection of Xueshuantong 600 mg and acutobin injection 0.75 U added to 0.9% sodium chloride injection 250 mL, once a day, for 14 days. The treatment group in the control group based on the use of mouse nerve growth factor 18 μg, intramuscular injection, once a day, for 14 days. The changes of American national institutes of health stroke scale(NIHSS) score and the Oxford disability score(OHS), the markedly effective rate and total effective rate of treatment, and the side effects of 2 groups of patients were observed. RESULTS The efficacy of the treatment group was significantly superior to the control group(P<0.05). Before treatment, there was no statistically significant of the NIHSS score and OHS score between treatment group and control group; On the 21th day of treatment, the the NIHSS score and OHS score of treatment group was significantly better than that of the control group. At the twenty-first day of treatment, the treatment group obvious effective rate(72.1%) and total effective rate(94.1%) were significantly higher than that of the control group(respectively 58.8% and 86.8%). CONCLUSION Mouse nerve growth factor combined with acutobin injection more effectively improves the nerve function of patients with acute cerebral infarction, and is superior to the single use of acutobin injection. |
| Key words: mouse nerve growth factor acutobin injection cerebral infarction efficacy |
